Ceftriaxone
n = 120 testedInspect counts and calculation
102 susceptible (S) + 5 intermediate (I) + 13 resistant (R) = 120 tested.
S% = (102 ÷ 120) × 100. Intermediate is not counted as susceptible here.
102 susceptible (S) + 5 intermediate (I) + 13 resistant (R) = 120 tested.
S% = (102 ÷ 120) × 100. Intermediate is not counted as susceptible here.
107 susceptible (S) + 3 intermediate (I) + 5 resistant (R) = 115 tested.
S% = (107 ÷ 115) × 100. Intermediate is not counted as susceptible here.
84 susceptible (S) + 8 intermediate (I) + 28 resistant (R) = 120 tested.
S% = (84 ÷ 120) × 100. Intermediate is not counted as susceptible here.
101 susceptible (S) + 4 intermediate (I) + 5 resistant (R) = 110 tested.
S% = (101 ÷ 110) × 100. Intermediate is not counted as susceptible here.
THE LESSON
18 of 20 and 90 of 100 are both 90%. Their approximate 95% Wilson intervals are 70–97% and 83–94%. More observations narrow sampling uncertainty; they do not remove sampling bias.
THE BOUNDARY
Unit, specimen, collection methods, testing selection, and time period all affect interpretation. These invented counts do not represent any hospital, region, patient, or clinical recommendation.
Download synthetic cohort CSVAll rows are deterministic teaching fixtures created for this portfolio. Period A is a separate synthetic comparison, not a real historical trend. S + I + R equals each agent’s tested count; untested isolates are not added to the denominator. The display suppresses n < 30 unless deliberately revealed. Wilson intervals describe binomial sampling uncertainty, not clinical appropriateness. Rounded percentage-point changes are descriptive, not a significance test.
Real antibiograms require laboratory-verified results, appropriate isolate de-duplication, current breakpoints, and consistent reporting. See CLSI M39 ↗ for the reporting framework. This demonstration does not claim full M39 compliance.
Educational software only. Not for diagnosis, treatment selection, dosing, or patient care.